摘要
目的探讨瑞舒伐他汀对2型糖尿病(T2DM)合并冠心病(CHD)患者血糖、血管内皮功能及炎症细胞因子水平的影响。方法选取2016年1月至2017年12月该院收治T2DM合并CHD患者240例作为研究对象,按照随机数字表法将其分为对照组与研究组,每组各120例。对照组患者给予常规治疗,研究组患者在常规治疗基础上加用瑞舒伐他汀钙片(每次10mg,1次/天),2组患者均连续治疗2个月。比较治疗前后2组患者的血糖指标[空腹血糖(FBG)、餐后2h血糖(2hPG)、空腹胰岛素(FINS)、餐后2h胰岛素(INS)、糖化血红蛋白(HbA1c)],血管内皮功能指标[可溶性细胞间黏附分子(sICAM-1)、可溶性血管细胞间黏附分子(sVCAM-1)、单核细胞趋化因子(MCP-1)、肱动脉血流介导的血管舒张功能(FMD)],炎症细胞因子[C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)]及不良反应情况。结果治疗前,2组各项观察指标比较,差异均无统计学意义(P>0.05)。治疗后,对照组的FBG、2hPG、HbA1c、CRP、TNF-α及IL-6水平显著降低,FINS及INS水平均显著增高,差异均有统计学意义(P<0.05),研究组FBG、2hPG、HbA1c、sICAM-1、sVCAM-1、MCP-1、CRP、TNF-α及IL-6水平显著降低,FINS、INS水平及FMD均显著增高,差异均有统计学意义(P<0.05);2组的血糖指标及不良反应发生率,比较差异均无统计学意义(P>0.05),血管内皮功能指标及炎症细胞因子水平比较,差异均有统计学意义(P<0.05)。结论瑞舒伐他汀能够显著改善T2DM合并CHD患者的血管内皮功能及炎性反应,且不影响血糖。
Objective To investigate the effects of rosuvastatin on blood glucose,vascular endothelial function and inflammatory cytokine levels in patients with type 2 diabetes mellitus (T2DM) complicated with coronary heart disease (CHD). Methods From January 2016 to December 2017,240 patients with T2DM and CHD were enrolled in the hospital.Subjects were divided into control group and study group according to random number method,with 120 cases in each group.Patients in the control group were given routine treatment,and patients in the study group were given rosuvastatin calcium tablets (10 mg/time,once/day) on a routine basis.Both groups of patients were treated continuously for 2 months.Blood glucose levels (FBG,postprandial 2 h blood glucose,FINS,INS,HbA1c) were compared between the two groups before and after treatment.The vascular endothelial function indexes (sICAM-1,sVCAM-1,MCP-1,FMD) were compared between the two groups before and after treatment.The inflammatory cytokines (CRP,TNF-α,IL-6) and adverse reactions were compared between the two groups before and after treatment. Results Before treatment,there was no significant difference in the observation indexes between the two groups ( P >0.05).After treatment,FBG,2 h postprandial blood glucose,HbA1c,CRP,TNF-α and IL-6 levels in the control group were significantly decreased,and FINS and INS levels were significantly increased,the difference was statistically significant( P <0.05).The FBG,2 h postprandial blood glucose,HbA1c,sICAM-1,sVCAM-1,MCP-1,CRP,TNF-α and IL-6 levels in the study group were significantly decreased,and FINS,INS levels and FMD were significantly increased.The difference was statistically significant( P <0.05).There were no significant differences in blood glucose levels and adverse reactions between the two groups ( P >0.05).There were significant differences in the indexes of vascular endothelial function and inflammatory cytokines between the two groups ( P <0.05). Conclusion Cersulfastatin can significantly improve vascular endothelial fun
作者
张义全
雷芳
丁娟
ZHANG Yiquan;LEI Fang;DING Juan(Department of Cardiology,People′s Hospital of Chongqing Hi-tech District,Chongqing 400039,China)
出处
《现代医药卫生》
2019年第9期1346-1348,1351,共4页
Journal of Modern Medicine & Health
关键词
2型糖尿病
冠心病
瑞舒伐他汀
血糖
血管内皮功能
炎症细胞因子
Type 2 diabetic mellitus
Coronary heart disease
Rosuvastatin
Blood glucose
Vascular endothelial function
Inflammatory factors
